NCT05685602 2026-03-19
CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
4 trialsNCT06696768 2026-03-19
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05187182 2026-03-18
CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT07107750 2026-02-04
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Not yet recruiting